Efficacy and Safety of Salonsip Compared to Sabiá Plaster (SAL-SIP-03/09)

H

Hisamitsu Farmaceutica do Brasil Ltda

Status and phase

Unknown
Phase 3

Conditions

Tendonitis
Myalgia
Contusions
Sprains
Pain

Treatments

Drug: Salonsip plaster
Drug: Sabia plaster

Study type

Interventional

Funder types

Industry

Identifiers

NCT00970658
SAL-SIP-03/09

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy in reducing signs and symptoms in patients with contusions, sprains, muscular injuries and injuries with less than 24 hours early or holders of myalgia, pain and tendonitis in regions miofasciais articulated with Salonsip compared to Sabiá plaster. It is clinical, open, multicenter, randomized, prospective and comparative, with patients entering at random. Patients will be included in sufficient quantity to achieve the minimum number of 70 evaluable patients.

Enrollment

70 estimated patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients of both sexes, of any race, aged 12 years;
  • Ability to read, understand and sign the Consent Form, in the case of children under age monitoring and consent of the person responsible;
  • Clinical diagnosis of bruises, sprains, trauma, muscle damage occurring in times less than 24 hours or myalgia, pain miofasciais or tendonitis.
  • Patients able to understand and maintain the clinical protocol

Exclusion criteria

  • Known hypersensitivity to components of the formulas of both the product and the comparative test.
  • Known hypersensitivity to paracetamol.
  • Location of the lesion with skin wound or irritated.
  • Hepatic or renal diseases known.
  • Pregnant or breastfeeding.
  • Patients who require surgery or immobilization rigid;
  • Patients with fractures or rupture of the ligaments.
  • Patients in use of anticoagulants.
  • Patients with severe concomitant systemic diseases such as cancer, diabetes, congenital or acquired heart disease, hematological diseases, convulsive disorders, autoimmune diseases, renal failure, infections, hormonal disorders and pulmonary disorders.
  • History of alcoholism or use of illicit drugs;
  • Use of non-steroidal anti-inflammatory drugs, corticosteroids or venoterápicos, topics or any other form of administration.
  • Conditions which in the opinion of the investigator makes the patient unsuitable to participate in the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

70 participants in 2 patient groups

Salonsip
Experimental group
Description:
The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
Treatment:
Drug: Salonsip plaster
Sabiá
Active Comparator group
Description:
The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
Treatment:
Drug: Sabia plaster

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems